Quick Facts
Plain-English Summary
DSIP (Delta Sleep-Inducing Peptide) is an endogenous nonapeptide discovered in 1977 by Marcel Monnier and colleagues at the University of Basel. In a landmark series of experiments, Monnier's group electrically stimulated the intralaminar thalamic nuclei of rabbits to induce slow-wave sleep, then collected dialysate from cerebral venous blood and transfused it into waking recipient animals. The recipients consistently entered deep, delta-wave sleep — pointing to a transferable sleep-promoting factor. The active fraction was isolated and sequenced, yielding the nine-amino-acid peptide now known as DSIP.
The discovery triggered an intensive period of research through the late 1970s and 1980s. DSIP was found not only in the brain but in peripheral tissues — pituitary, hypothalamus, gut, and plasma — suggesting it functions as a regulatory signal rather than a purely central neuropeptide. Researchers reported that it could modulate somatostatin and GHRH release, attenuate the hypothalamic-pituitary-adrenal (HPA) axis response to stress, and demonstrate antioxidant properties in vitro.
Small-scale human trials conducted primarily in the 1980s and early 1990s provided what remains the most clinically relevant data available: intravenous DSIP reduced sleep latency and increased the proportion of slow-wave sleep in patients with insomnia and in healthy volunteers, as documented by polysomnography. Some studies also reported reductions in cortisol during stress states. These findings were published in peer-reviewed journals and constitute a genuine, if limited, body of human evidence.
The human evidence base for DSIP is real but significantly dated. The trials were small (typically 5–20 subjects), conducted over 30 years ago, and used IV administration — a route not reflective of how the compound is self-administered today. No modern randomised controlled trial has been conducted, and the research program effectively stalled after the early 1990s.
Today, DSIP occupies a niche position in the research peptide community, discussed primarily in the context of insomnia, stress resilience, and neuroprotection. Its extremely short plasma half-life (~15 minutes) creates a fundamental bioavailability challenge: the peptide is rapidly degraded by endopeptidases before it can reach central targets via subcutaneous or oral routes. Intranasal administration has been studied as a potential solution, but published data on this route remains limited. This pharmacokinetic obstacle is often underacknowledged in community discussions of DSIP.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Rabbit sleep induction (Monnier et al., 1977) | Transfusion of dialysate collected during electrically induced delta sleep reproducibly induced slow-wave sleep in waking recipients. The active fraction was isolated and identified as DSIP. Foundational discovery study. Monnier et al. 1977 ↗ | Preclinical |
| Rat sleep polysomnography | IV DSIP increased delta-wave amplitude and slow-wave sleep duration in rodent EEG studies. Effects were dose-dependent but inconsistent across subsequent replication attempts. | Preclinical |
| Rat stress / corticosterone | Attenuated corticosterone elevation in restraint stress and other paradigms. Proposed mechanism: HPA axis dampening at hypothalamic level. Graf & Kastin 1984 ↗ | Preclinical |
| In vitro antioxidant | Inhibited lipid peroxidation and scavenged reactive oxygen species in cell culture and rat brain homogenate models. Neuroprotective effects proposed but not established in vivo in humans. | Preclinical |
| Rat neuroendocrine modulation | Modulated somatostatin and GHRH dynamics; in some models facilitated GH release during sleep periods. Mechanistic interpretation remains contested in the literature. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Scherschlicht et al. — polysomnographic series | Small cohorts of insomnia patients and healthy volunteers; IV DSIP; polysomnographic monitoring | — | Limited · Small N |
| Schneider-Helmert — insomnia series | Chronic insomnia patients; IV DSIP over multiple nights; subjective and objective sleep measures | — | Limited · Small N |
| HPA axis / cortisol studies | Healthy volunteers under stress protocols; IV DSIP | — | Limited · Small N |
| All non-IV routes; all indications post-1995 | — | — | No Data |
DSIP has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
DSIP's approximately 15-minute plasma half-life means systemic exposure is inherently time-limited. Rapid degradation by plasma endopeptidases constrains both therapeutic duration and potential for systemic accumulation. This pharmacokinetic profile reduces but does not eliminate safety concerns, particularly around route and dose uncertainty.
The fundamental safety problem with DSIP in current self-administration contexts is that plasma concentrations achieved via subcutaneous injection are largely unknown. Human PK data for any non-IV route does not exist in the published literature. Users cannot verify whether active doses are being achieved or what concentrations are reached — making risk characterisation impossible.
- Injection site redness and mild soreness
- Transient fatigue or drowsiness following administration
- Vivid or unusual dreams reported by some users
- Mild headache in early days of use
- No pharmacovigilance database exists for DSIP
- Pregnancy or breastfeeding
- Active sleep disorders under medical management
- Concurrent use of sedative or hypnotic medications
- Endocrine or hormonal conditions
- Children and adolescents
- Immunosuppressive therapy
DSIP is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of DSIP for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
What makes DSIP interesting from an evidence standpoint is that the human data actually exists — which puts it ahead of most peptides in this space. Schneider-Helmert's work in the 1980s used proper polysomnography, not just self-report. You can see the delta-wave changes in the EEG traces. The problem is it's 40-year-old data from IV administration in tiny cohorts. Nobody has run a modern equivalence study. The gap between "there is human data" and "we understand how this works in humans" is enormous.
Right, and the administration route gap is underappreciated. DSIP has a plasma half-life of around 15 minutes. In the IV studies, they're putting it directly into circulation and still measuring effects. With subcutaneous injection, you're adding an absorption step that the peptide may not survive long enough to complete meaningfully. There's no published PK data for subQ DSIP in humans. People are dosing blind.
The historical context matters here. DSIP research peaked when sleep medicine was a much younger field and the tools for characterising neuropeptide function were relatively primitive. Monnier's original work was genuinely innovative for 1977. But the research program never evolved into the translational stage — no Phase II trials with modern endpoints, no pharmacokinetic profiling in humans, no receptor identification. The compound got orphaned when funding priorities shifted in the 1990s. What we're left with is a scientifically credible but frozen evidence base.
The cortisol attenuation finding is the piece I find most mechanistically plausible. The HPA axis is accessible via hypothalamic neuropeptide signalling and DSIP's distribution in hypothalamic tissue is documented. The problem is the human studies showing cortisol reduction were done under controlled stress induction — not naturalistic stress, not chronic stress conditions. The leap from "IV DSIP reduced cortisol in a laboratory stress paradigm in the 1980s" to "DSIP will fix your stress response" is very long and unsupported by the current evidence.
This is a good framing. DSIP is a compound where the underlying science is legitimate, the early findings are genuinely interesting, and the gap between what was found and what's being claimed in vendor copy is enormous. It's not implausible — it's just unfinished. Thirty years of unfinished.
From a formulation perspective, the intranasal route is probably the most defensible option for DSIP — bypassing first-pass plasma degradation and offering a more direct CNS-accessible delivery. There's some animal data supporting this, and DSIP is structurally small enough to have meaningful mucosal permeability. But there's no published human intranasal PK data. For anyone self-experimenting with subQ DSIP, the honest answer is: you probably aren't achieving what the 1980s IV trials achieved, and we don't know what you are achieving.